Key result
Silencing CaMKIIδ and Wenxin Keli suppressed Ang II-induced cardiomyocyte hypertrophy by blocking CnA-NFAT and inflammatory signaling pathways in H9c2 cells.
Why the study?
The interaction between CaMKII and CnA-NFAT signaling pathways in cardiac hypertrophy remains unclear.
Inhibiting CaMKII, but not CnA, may be a promising approach to attenuate cardiomyocyte hypertrophy and arrhythmia progression based on in vitro findings.
In vitro CaMKIIδ inhibition may attenuate hypertrophy; leaves open in vivo validation before any clinical consideration.
Previous studies have demonstrated that calcium‐/calmodulin‐dependent protein kinase II (CaMKII) and calcineurin A‐nuclear factor of activated T‐cell (CnA‐NFAT) signaling pathways play key roles in cardiac hypertrophy (CH). However, the interaction between CaMKII and CnA‐NFAT signaling remains unclear. H9c2 cells were cultured and treated with angiotensin II (Ang II) with or without silenced CaMKIIδ (siCaMKII) and cyclosporine A (CsA, a calcineurin inhibitor) and subsequently treated with Wenxin Keli (WXKL). Patch clamp recording was conducted to assess L‐type Ca2+ current (ICa-L), and the expression of proteins involved in signaling pathways was measured by western blotting. Myocardial cytoskeletal protein and nuclear translocation of target proteins were assessed by immunofluorescence. The results indicated that siCaMKII suppressed Ang II‐induced CH, as evidenced by reduced cell surface area and ICa-L. Notably, siCaMKII inhibited Ang II‐induced activation of CnA and NFATc4 nuclear transfer. Inflammatory signaling was inhibited by siCaMKII and WXKL. Interestingly, CsA inhibited CnA‐NFAT pathway expression but activated CaMKII signaling. In conclusion, siCaMKII may improve CH, possibly by blocking CnA‐NFAT and MyD88 signaling, and WXKL has a similar effect. These data suggest that inhibiting CaMKII, but not CnA, may be a promising approach to attenuate CH and arrhythmia progression.
No takes yet. Share an insight, caveat, or question.
An et al. (2020) studied Cardiac hypertrophy. Silenced CaMKIIδ (siCaMKII) and Wenxin Keli (WXKL) vs. Angiotensin II alone / Cyclosporine A was evaluated on Cardiomyocyte hypertrophy (cell surface area, ICa-L, and signaling pathway expression). Silencing CaMKIIδ and Wenxin Keli suppressed Ang II-induced cardiomyocyte hypertrophy by blocking CnA-NFAT and inflammatory signaling pathways in H9c2 cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: